Thalia Therapeutics Plc (LON:THAT)
0.64p-1.92%
Spriggl Score: Weak— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Phase one data arrives next year; directors back the bet but heavy dilution and cash burn remain serious concerns.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Thalia Therapeutics Plc
Thalia Therapeutics Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an…
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- £5.4M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Thalia Therapeutics Plc and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free